Antipsychotic medication prescription patterns in adults with developmental disabilities who have experienced psychiatric crisis

Research in Developmental Disabilities

Volumn 33, Issue 1, 2012, Pages 32-38

  Lunsky, Yona ^a,b   Elserafi, Jonny ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Developmental disability; Medications

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG USE; FEMALE; GENDER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PERSONALITY DISORDER; POLYPHARMACY; PREDICTION; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; PSYCHOSEXUAL DISORDER; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; DEVELOPMENTAL DISABILITIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

ADULT; DISABILITY;

EID: 80053446310     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2011.08.003     Document Type: Article

References (22)

1. Baumeister A.A., Sevin J.A., King B.H. Neuroleptic medications. Psychotropic medications and developmental disabilities: The international consensus handbook 1998, 133-150. Ohio State University Nisonger Center, Columbus, OH. S. Reiss, M.G. Aman (Eds.).
2. Beange H., McElduff A., Baker W. Medical disorders of adults with mental retardation: A population study. American Journal on Mental Retardation 1995, 99:595-604.
3. Burd L., Williams M., Klug M.G., Fjelstad K., Schimke A., Kerbeshian J. Prevalence of psychotropic and anticonvulsant drug use among North Dakota group home residents. Journal of Intellectual Disability Research 1997, 41:488-494.
4. DeKuijper G., Hoekstra P., Visser F., Scholte F.A., Penning C., Evenhuis H. Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disability Research 2010, 54:659-667.
5. Hasnain M., Vieweg W.V.R., Fredrickson S.K., Beatty-Brooks M., Fernandez A., Pandurangi A.K. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Primary Care Diabetes 2009, 3:5-15.
6. Hassiotis A., Robotham D., Canagasabey A., Romeo R., Langridge D., Blizard R., King M. Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behaviour in adults with intellectual disabilities. American Journal of Psychiatry 2009, 166:1278-1285.
7. Hurley A.D., Folstein M., Lam N. Patients with and without intellectual disability seeking outpatient psychiatric services: Diagnoses and prescribing pattern. Journal of Intellectual Disability Research 2003, 47:39-50.
8. Lott I.T., McGregor M., Engelman L., Touchette P., Tournay A., Sandman C., Walsh D. Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records. Journal of Intellectual Disability Research 2004, 48:563-571.
9. Marshall T. Audit of the use of psychotropic medication for challenging behaviour in a community learning disability service. Psychiatric Bulletin 2004, 28:447-450.
10. Matson J.L., Mahan S. Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities 2010, 31:1570-1576.
11. Matson J.L., Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities 2009, 30:572-586.
12. Matson J.L., Rivet T.T., Fodstad J.C. Atypical antipsychotic adjustments and side-effects over time in adults with intellectual disability, tardive dyskinesia, and akathisia. Journal of Developmental and Physical Disabilities 2010, 24:447-461.
13. McGillivray J.A., McCabe M.P. Emerging trends in the use of drugs to manage the challenging behaviour of people with intellectual disability. Journal of Applied Research in Intellectual Disabilities 2006, 19:163-172.
14. Molyneux P., Emerson E., Caine A. Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. Journal of Applied Research in Intellectual Disabilities 1999, 12:46-57.
15. Robertson J., Emerson E., Gregory N., Hatton C., Kessissoglou S., Hallam A. Receipt of psychotropic medication by people with intellectual disability in residential settings. Journal of Intellectual Disability Research 2000, 44:666-676.
16. Spreat S., Conroy J.W., Fullerton A. Statewide longitudinal survey of psychotropic medication use of persons with mental retardation: 1994-2000. American Journal on Mental Retardation 2004, 109:322-331.
17. Stolker J.J., Heerdink E.R., Leufkens H.G.M., Clerkx M.G.M., Nolen W.A. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. General Hospital Psychiatry 2001, 23:345-349.
18. Sulliva W.F., Berg J.M., Bradley E., Cheetham T., Denton R., Heng J., Hennen B., Joyce D., Kelly M., Korossy M., Lunsky Y., McMillian S. Primary care of adults with developmental disabilities: Canadian consensus guidelines. Canadian Family Physician 2011, 57:541-553.
19. Szymanski L., King B.H. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry 1999, 38:5S-31S.
20. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., Crawford M. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomized controlled trial. Lancet 2008, 371:57-63.
21. Ucok A., Gaebel W. Side effects of atypical antipsychotics: A brief overview. World Psychiatry 2008, 7:58-62.
22. Wood D., Hall A.G., Zhang J., Hao T. Predictors of psychoactive medication use by persons on the MR/DD home and community based waiver 2006, Agency for Health Care Administration, Tallahassee, Florida.